Differential effects of prazosin and naftopidil on pelvic blood flow and nitric oxide synthase levels in spontaneously hypertensive rats

Journal of Receptors and Signal Transduction

Volumn 28, Issue 4, 2008, Pages 403-412

  Yono, Makoto ^a   Yamamoto, Yasuhiro ^a   Imanishi, Aya ^a   Yoshida, Masaki ^a   Ueda, Shoichi ^a   Latifpour, Jamshid ^b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Blood flow; Naftopidil; Nitric oxide synthase; Prazosin; Rat

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLAZOSIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MESSENGER RNA; MICROSPHERE; NAFTOPIDIL; NEURONAL NITRIC OXIDE SYNTHASE; PRAZOSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER; BLOOD FLOW; CONTROLLED STUDY; DRUG EFFECT; FLUORESCENCE ANALYSIS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; ILIAC ARTERY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PELVIS BLOOD FLOW; PENILE BLOOD FLOW; PROSTATE; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPONTANEOUSLY HYPERTENSIVE RAT; UPREGULATION; WISTAR KYOTO RAT;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; HYPERTENSION; MALE; NAPHTHALENES; NITRIC OXIDE SYNTHASE; PELVIS; PENIS; PIPERAZINES; PRAZOSIN; PROSTATE; QUINAZOLINES; QUINOXALINES; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTORS, ADRENERGIC, ALPHA; REGIONAL BLOOD FLOW; URINARY BLADDER;

RATTUS;

EID: 49649117798     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.1080/10799890802176626     Document Type: Article

References (23)

1. Akduman B, Crawford ED. Terazosin, doxazosin, and prazosin: Current clinical experience. Urology 2001, 58(6 Suppl. 1), 49-54.
2. Dunn CJ, Matheson A, Faulds DM. Tamsulosin: A review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging 2002, 19, 135-161.
3. Kaplan SA, De Rose AF, Kirby RS, O'leary MP, McVary KT. Beneficial effects of extended-release doxazosin and doxazosin standard on sexual health. BJU Int 2006, 97, 559-566.
4. Yono M, Yamamoto Y, Yoshida M, Ueda S, Latifpour J. Effects of doxazosin on blood flow and mRNA expression of nitric oxide synthase in the spontaneously hypertensive rat genitourinary tract. Life Sci 2007, 81, 218-222.
5. Andersson KE, Chapple CR, Hofner K. Future drugs for the treatment of benign prostatic hyperplasia. World J Urol 2002, 19, 436-442.
6. 1-adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int 2001, 88(Suppl. 2), 27-34.
7. Giardinà D, Gulini U, Massi M, Piloni MG, Pompei P, Rafaiani G, Melchiorre C. Structure-activity relationships in prazosin-related compounds. 2. Role of the piperazine ring on α-blocking activity. J Med Chem 1993, 36, 690-698.
8. Pescalli N, Sala V, Sponer G, Ceserani R. Effects of naftopidil on some urodynamic parameters and arterial blood pressure in comparison with prazosin in conscious rats. Pharmacol Res 1996, 34, 121-124.
9. Yono M, Takahashi W, Pouresmail M, Johnson DR, Foster HE Jr, Weiss RM, Latifpour J. Quantification of endothelins, their receptors, and endothelin-converting enzyme mRNAs in rat genitourinary tract using real-time RT-PCR. J Pharmacol Toxicol Methods 2002, 48, 87-95.
10. Nishi K, Wada Y, Saito M, Foster HE Jr, Weiss RM, Latifpour J. Properties of alpha-1-adrenergic receptors in the rat prostate: Effect of experimental diabetes. Urol Int 1998, 61, 147-153.
11. Persson K, Pandita RK, Spitsbergen JM, Steers WD, Tuttle JB, Andersson KE. Spinal and peripheral mechanisms contributing to hyperactive voiding in spontaneously hypertensive rats. Am J Physiol 1998, 275, R1366-R1373.
12. Steers WD, Clemow DB, Persson K, Sherer TB, Andersson KE, Tuttle JB. The spontaneously hypertensive rat: insight into the pathogenesis of irritative symptoms in benign prostatic hyperplasia and young anxious males. Exp Physiol 1999, 84, 137-147.
13. Golomb E, Rosenzweig N, Eilam R, Abramovici A. Spontaneous hyperplasia of the ventral lobe of the prostate in aging genetically hypertensive rats. J Androl 2000, 21, 58-64.
14. Hale TM, Okabe H, Bushfield TL, Heaton JP, Adams MA. Recovery of erectile function after brief aggressive antihypertensive therapy. J Urol 2002, 168, 348-354.
15. Lepor H. The evolution of alpha-blockers for the treatment of benign prostatic hyperplasia. Rev Urol 2006, 8(Suppl. 4), S3-S9.
16. Lepor H, Jones K, Williford W. The mechanism of adverse events associated with terazosin: an analysis of the Veterans Affairs cooperative study. J Urol 2000, 163, 1134-1137.
17. Takei R, Ikegaki I, Shibata K, Tsujimoto G, Asano T. Naftopidil, a novel α1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human α1-adrenoceptors. Jpn J Pharmacol 1999, 79, 447-454.
18. Hampel C, Dolber PC, Smith MP, Savic SL, Th roff JW, Thor KB, Schwinn DA. Modulation of bladder α1-adrenergic receptor subtype expression by bladder outlet obstruction. J Urol 2002, 167, 1513-1521.
19. Sugaya K, Nishijima S, Miyazato M, Ashitomi K, Hatano T, Ogawa Y. Effects of intrathecal injection of tamsulosin and naftopidil, alpha-1A and -1D adrenergic receptor antagonists, on bladder activity in rats. Neurosci Lett 2002, 328, 74-76.
20. Gotoh M, Kamihira O, Kinukawa T, Ono Y, Ohshima S, Origasa H. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: A randomized controlled trial. BJU Int 2005, 96, 581-586.
21. Nishino Y, Masue T, Miwa K, Takahashi Y, Ishihara S, Deguchi T. Comparison of two α1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: A randomized crossover study. BJU Int 2006, 97, 747-751.
22. Tarcan T, Azadzoi KM, Siroky MB, Goldstein I, Krane RJ. Age-related erectile and voiding dysfunction: the role of arterial insufficiency. Br J Urol 1998, 82(Suppl. 1), 26-33.
23. McVary KT. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 2005, 47, 838-845.